## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?**
- Source: Yahoo Finance Singapore | 20251227T140734 | Somewhat-Bullish | Relevance: 100%
- Despite a recent 6.5% decline in Abbott Laboratories' stock, the article suggests its strong financials, particularly an impressive 27% Return on Equity (ROE), might indicate the market is underestimating its potential. The company's ROE significantly surpasses the industry average of 9.8%, and it has maintained a modest 18% net income growth over five years. However, future analyst estimates predict a decline in ROE and earnings, despite a projected decrease in its payout ratio.

**2. What you need to know ahead of Abbott Laboratories' earnings release**
- Source: MSN | 20251226T140750 | Neutral | Relevance: 100%
- This article provides a preview of Abbott Laboratories' upcoming earnings release. It will likely cover key financial expectations, analyst projections, and any significant operational updates or challenges facing the company. Investors will be looking for insights into ABT's performance and future outlook.

**3. What You Need to Know Ahead of Abbott Laboratories' Earnings Release**
- Source: FinancialContent | 20251226T110737 | Somewhat-Bullish | Relevance: 100%
- Abbott Laboratories (ABT) is expected to announce its fiscal Q4 earnings for 2025 soon, with analysts anticipating a profit of $1.50 per share, an 11.9% increase year-over-year. Despite mixed Q3 results where net sales missed estimates but EPS met expectations, Wall Street maintains a "Strong Buy" rating for ABT, forecasting a 17.5% potential upside. The company has consistently met or surpassed bottom-line estimates in the past four quarters.

**4. Avanza Fonder AB Purchases 10,889 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251226T091138 | Bullish | Relevance: 100%
- Avanza Fonder AB increased its stake in Abbott Laboratories (NYSE:ABT) by 6.5% during the third quarter, purchasing an additional 10,889 shares to hold a total of 179,290 shares valued at $24.01 million. This makes Abbott Laboratories the 21st largest holding for the fund, representing approximately 0.6% of its investment portfolio. Other institutional investors also modified their holdings, and Abbott Laboratories recently announced a quarterly dividend increase to $0.63 per share.

**5. Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms**
- Source: ts2.tech | 20251225T211559 | Neutral | Relevance: 100%
- Abbott Laboratories (ABT) is ending 2025 with significant developments, including FDA approval for its Volt PFA system for AFib treatment, an expansion of its Lingo biowearable to Android, and a planned $23 billion acquisition of Exact Sciences to boost its diagnostics segment. However, the company is also navigating an FDA early alert regarding incorrect low glucose readings from some FreeStyle Libre 3/3 Plus sensors. Analysts remain broadly constructive on ABT, with a consensus 12-month price target around $147, as the company layers new products and strategic M&A onto a solid growth base while managing product-related risks.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.0x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.3B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.0 |
| Current P/E | 24.1 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.4% to -2.1% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.15% (CS: 21) | Weak |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 0.960x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.84
- **Stop Loss:** $120.34 (3.6% risk)
- **Target:** $129.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 293
- **Position Value:** $36,578.12
- **Portfolio %:** 36.58%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*